TR-Pharm will manufacture the drug substance and drug product upon completion of its facility investment in Turkey
Dr Reddy’s and TR-Pharm entered into a strategic collaboration agreement for manufacture and commercialization of a portfolio of biosimilar drugs in Turkey.
Dr Reddy’s Laboratories and TR-Pharm announced a strategic collaboration agreement involving three biosimilar products. A total of three products will be registered and subsequently commercialised as a part of this agreement by TR-Pharm in Turkey. TR-Pharm will also manufacture the drug substance and drug product upon completion of its facility investment.
TR-Pharm has begun laying out the groundwork for the technology transfer. This collaboration will be an important component of TR-Pharm’s ongoing biological product development and manufacturing business in the region. The partnership will also enable Dr Reddy’s to widen the global footprint of its biosimilar business.
Comments are closed.